Zylotrim, LLC Participates In ERSP Forum

New York, NY – Mar. 23, 2009 – The Electronic Retailing Self-Regulation Program (ERSP) has determined that Zylotrim, LLC, which markets the Zylotrim Weight Loss Supplement, has provided reliable support for certain establishment claims but recommended the marketer modify or discontinue others.  The marketer’s advertising came to ERSP’s attention pursuant to its ongoing monitoring efforts.

ERSP, the electronic direct-response industry’s self-regulatory forum, is administered by  the Council of Better Business Bureaus (CBBB) with policy oversight by  the National Advertising Review Council (NARC).

ERSP’s inquiry focused on claims included in broadcast and online advertising. Claims at issue in the ERSP  inquiry included:

  • •           “Zylotrim will more than double the activity level of your fat burning enzymes making it easier to lose pounds of body fat and weight.”
  • •           ”Clinically proven  to more than  double the activity of fat burning enzymes.”
  • •           “Clinically proven  to help reduce body fat & weight.”
  • •           “Lose 200% more weight-clinically proven” / “In a recent double blind study participants who took Zylotrim lost 200% more weight than those who didn’t take it.”
  • •           “80% of each pound that was lost was pure body fat.”
  • •           “Rated #1 weight loss active ingredient.”

Following its review of the evidence, ERSP  determined that the two controlled clinical human studies on 3-acetyl-7-oxo-dehydroepiandrosterone, or 7-Keto DHEA, provided reliable support for the marketer’s establishment claim of 200% increased weight loss when using the product in combination with diet and exercise as compared to subjects who simply dieted and exercised. Additionally, ERSP determined the marketer provided a reasonable basis for the claim that the product has been  “Clinically proven  to help reduce body fat & weight.”

However, ERSP  concluded that the marketer’s evidence did  not adequately support the claim that the product is “Clinically proven  to more than  double the activity of fat burning enzymes” or that ”80% of each pound that was lost was pure body fat” and recommended that these claims be either modified or discontinued.

Finally, ERSP  determined that the “Rated #1 Weight Loss Active Ingredient” claim is inaccurate and should be either modified or discontinued in the current  context  in which the claim is presented in the advertising and on the product packaging.

The company,  in its marketer’s statement said “… it certainly respects ERSP’s conclusions and recommendations and will modify these claims in future advertising.”